EVIDENCE OF SIMILAR INCREASES IN BONE TURNOVER DURING NAFARELIN AND DANAZOL USE IN WOMEN WITH ENDOMETRIOSIS

被引：15

作者：

YLIKORKALA, O

NILSSON, CG

HIRVONEN, E

VIINIKKA, L

机构：

[1] Second Department of Obstetrics and Gynecology, Children's Hospital, University of Helsinki, and Minerva Foundation Institute for Medical Research

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1990年 / 4卷 / 04期

关键词：

D O I：

10.3109/09513599009024979

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Medical 'oophorectomy' by GnRH agonist or danazol is an effective treatment for endometriosis. Since increased bone loss is a potential risk of hypoestrogenism, we compared the effect of nafarelin and danazol treatment on bone metabolism. Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400-mu-g day intranasally) and six patients danazol (600 mg day orally) for 6 months. Both treatments had already led to hypoestrogenism (E2 < 21.6 pg/ml) after 3 months. They both were accompanied by an approximately 50% rise in 24-h urinary hydroxyproline output, suggesting accelerated bone resorption at 6 months; yet urinary calcium output did not change significantly. Serum osteocalcin rose by 80-120% and bone alkaline phosphatase activity by 34-40%, suggesting stimulated bone formation at the same time. No detectable changes ensued in cortical bone mineral content in the distal radius or in serum levels of calcium, calcitonin, parathyroid hormone, or aminoterminal propeptide of type III collagen. Three months after treatment, hydroxyproline output, serum osteocalcin and bone alkaline phosphatase were still elevated in women taking nafarelin, whereas only serum osteocalcin was elevated in women taking danazol. Our data thus suggest that bone turnover was increased during nafarelin and danazol therapy and that this effect was reversible.

引用

页码：251 / 260

页数：10

共 23 条

[1]

McLachlan R.I., Healy D.L., Burger H.G., Clinical aspects of LHRH analogues in gynaecology: a review, Br. J. Obstet. Gynaecol, 93, pp. 431-454, (1986)

[2]

Editorial LHRH analogues in endometriosis, Lancet, 2, pp. 1016-1018, (1986)

[3]

Editorial Uterine fibroids: medical treatment or surgery, Lancet, 2, (1986)

[4]

Lemay A., Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases, Fertil. Steril, 48, pp. 10-12, (1987)

[5]

Dmowski W.P., Endocrine properties and clinical application of danazol, Fertil. Steril, 31, pp. 237-251, (1979)

[6]

Barbieri R.L., Ryan K.J., Danazol: endocrine pharmacology and therapeutic applications, Am. J. Obstet. Gynecol, 141, pp. 453-463, (1981)

[7]

Gudmundsson J.A., Ljanghall S., Bergqvist C., Wide L., Nillius S.J., Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition, J. Clin. Endocrinol. Metab, 65, pp. 159-163, (1987)

[8]

Steingold K.A., Cedars M., Lu J.K.H., Randle D., Judd H.L., Meldrum D.R., Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist, Obstet. Gynecol, 69, pp. 403-411, (1987)

[9]

Johansen J.S., Riis B.J., Hassager C., Moen M., Jacobson J., Christiansen C., The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism, J. Clin. Endocrinol. Metab, 67, pp. 701-706, (1987)

[10]

Tummon I.S., Radwanska E., Ali A., Binor Z., Pepping M.E., Dmowski W.P., Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol, Fertil. Steril, 49, pp. 792-796, (1988)

← 1 2 3 →